Holen Sie sich die Stockscreener-App
16.45
7.09%
-1.3131
Schlusskurs vom Vortag:
$17.76
Offen:
$18.125
24-Stunden-Volumen:
958.54K
Relative Volume:
1.74
Marktkapitalisierung:
$376.01M
Einnahmen:
$59,000
Nettoeinkommen (Verlust:
$-78.26M
KGV:
-2.6978
EPS:
-6.0964
Netto-Cashflow:
$-51.46M
1W Leistung:
+18.45%
1M Leistung:
-4.68%
6M Leistung:
+17.86%
1J Leistung:
+184.48%
1-Tages-Spanne:
$16.32
$18.12
1-Wochen-Bereich:
$13.55
$18.12
52-Wochen-Spanne:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Firmenname
Avalo Therapeutics Inc
Sektor
Branche
Telefon
410-522-8707
Adresse
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
16.50 | 404.72M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-09-17 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-05 | Eingeleitet | TD Cowen | Buy |
| 2025-08-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-25 | Eingeleitet | Jefferies | Buy |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-28 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-21 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-10-24 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-04-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Avalo Therapeutics (NASDAQ:AVTX) Earns Market Outperform Rating from Analysts at Citizens Jmp - MarketBeat
Citizens Initiates Coverage on Avalo Therapeutics (AVTX) with Ma - gurufocus.com
Citizens JMP Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $52 - Moomoo
Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN
Citizens initiates Avalo Therapeutics stock with outperform rating By Investing.com - Investing.com India
Citizens initiates Avalo Therapeutics stock with outperform rating - investing.com
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
AVTX Technical Analysis & Stock Price Forecast - Intellectia AI
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Insider Sell Alert: Christopher Sullivan Sells Shares of Avalo T - gurufocus.com
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares - MarketBeat
Avalo Therapeutics CFO Sullivan sells $270k in stock - investing.com
Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock - investing.com
Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan - Stock Titan
Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares - Stock Titan
Wall Street experts anticipate Avalo Therapeutics (AVTX) could surge by 113.34%: Key Insights You Need to Know - Bitget
Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history - Yahoo Finance Singapore
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know - Yahoo Finance
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options - Stock Titan
Logos Global (AVTX) discloses 1,285,000-share position, including options - Stock Titan
AVTX SEC FilingsAvalo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Avalo Therapeutics (AVTX) director acquires 3,166 shares via RSU vesting - Stock Titan
Avalo Therapeutics (AVTX) director exercises 3,166 RSUs, holds 6,333 shares - Stock Titan
Director at Avalo Therapeutics (AVTX) converts 3,166 RSUs to stock - Stock Titan
Avalo Therapeutics (AVTX) CEO exercises RSUs, shares withheld for taxes - Stock Titan
Avalo Therapeutics (AVTX) CFO nets shares from RSU vesting and tax settlement - Stock Titan
Director at Avalo Therapeutics (AVTX) exercises 3,166 RSUs into common stock - Stock Titan
Director at Avalo Therapeutics (AVTX) gains 3,166 common shares - Stock Titan
Growth Recap: Can Avalo Therapeutics Inc grow without external fundingMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
US Stocks Recap: Can Avalo Therapeutics Inc outperform under higher oil pricesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to “Hold” at Wall Street Zen - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Volatility Watch: What analysts say about Avalo Therapeutics Inc stock2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Has Positive Outlook for AVTX Q1 Earnings - Defense World
Avalo Therapeutics' Jonathan Goldman and Mitchell Chan to Not Stand for Re-election - TradingView
Two Avalo Therapeutics (AVTX) directors to step down after 2026 meeting - stocktitan.net
Avalo Therapeutics, Inc. Announces Departure of Directors Dr. Jonathan Goldman and Mitchell Chan - marketscreener.com
HC Wainwright Issues Positive Outlook for AVTX Earnings - MarketBeat
Aug Macro: Is Avalo Therapeutics Inc a potential multi bagger2026 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $40.00 at HC Wainwright - Defense World
What date does Avalo Therapeutics's (AVTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Finanzdaten der Avalo Therapeutics Inc-Aktie (AVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avalo Therapeutics Inc-Aktie (AVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer |
Apr 01 '26 |
Sale |
16.77 |
7,979 |
133,770 |
25,318 |
| Doyle Mittie | Chief Medical Officer |
Apr 01 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
4,301 |
| Doyle Mittie | Chief Medical Officer |
Apr 01 '26 |
Sale |
16.00 |
679 |
10,864 |
3,622 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):